You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Derlin-1-immunopositive inclusions in patients with Alzheimers disease

Honjo, Yasuyukia,b; Ito, Hidefumib; Horibe, Tomohisaa; Shimada, Hiroyukic; Nakanishi, Akid; Mori, Hiroshic; Takahashi, Ryosukeb; Kawakami, Kojia

Neuroreport:
doi: 10.1097/WNR.0b013e3283552a75
Clinical Neuroscience and Neuropathology
Abstract

Amyloid plaques and neurofibrillary tangles are the major pathological hallmarks of Alzheimer’s disease. Neurofibrillary tangles are composed of filaments and paired helical filaments containing polymerized hyperphosphorylated tau protein. Derlin proteins are a family of proteins that are conserved in all eukaryotes, in which they function in endoplasmic reticulum-associated degradation. Protein disulfide isomerase (PDI) is a member of the thioredoxin superfamily and is believed to accelerate the folding of disulfide-bonded proteins in the luminal space of the endoplasmic reticulum. In this study, we found that derlin-1 and PDI were colocalized in neurofibrillary tangles in the brain of patients with Alzheimer’s disease. Derlin-1 and PDI may work as partners to avoid the accumulation of unfolded proteins in Alzheimer’s disease. Furthermore, we found that derlin-1 was immunopositive for neurofibrillary tangles and upregulated in Alzheimer’s disease and that derlin-1 may play an important role in endoplasmic reticulum-associated degradation during the pathogenesis of Alzheimer’s disease. We hypothesize that derlin-1 was upregulated to avoid the aggregation of unfolded proteins. Despite the upregulation of derlin-1, the functions of chaperone proteins and Alzheimer tau protein were lost and these proteins were also accumulated. Finally, they were involved in neurofibrillary tangles. These results suggest that derlin-1 may be associated with endoplasmic reticulum stress in neuronal cells in Alzheimer’s disease.

Author Information

aDepartment of Pharmacoepidemiology, Graduate School of Medicine and Public Health

bDepartment of Neurology, Facility of Medicine, Kyoto University, Koyoto

cDepartment of Neurology and Neuroscience, Osaka City University Medical School, Osaka

dDepartment of Neurology and Psychiatry, Osaka City Kosaiin Hospital, Osaka, Japan

Correspondence to Koji Kawakami, MD, PhD, Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoecho, Sakyoku, Kyoto 606-8501, Japan Tel: +81 75 753 4459; fax: +81 75 753 4469; e-mail: kawakami.koji.4e@kyoto-u.ac.jp

Received March 24, 2012

Accepted April 23, 2012

© 2012 Lippincott Williams & Wilkins, Inc.